CN117982549A - New application of lamp silver brain-dredging composition - Google Patents
New application of lamp silver brain-dredging composition Download PDFInfo
- Publication number
- CN117982549A CN117982549A CN202211355093.0A CN202211355093A CN117982549A CN 117982549 A CN117982549 A CN 117982549A CN 202211355093 A CN202211355093 A CN 202211355093A CN 117982549 A CN117982549 A CN 117982549A
- Authority
- CN
- China
- Prior art keywords
- composition
- silver brain
- lamp
- brain
- lamp silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 72
- 239000004332 silver Substances 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 210000001519 tissue Anatomy 0.000 claims abstract description 44
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 35
- 210000001072 colon Anatomy 0.000 claims abstract description 27
- 230000000968 intestinal effect Effects 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 23
- 210000003405 ileum Anatomy 0.000 claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 claims abstract description 16
- 210000002175 goblet cell Anatomy 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 241000521092 Alloprevotella Species 0.000 claims abstract description 8
- 241000605716 Desulfovibrio Species 0.000 claims abstract description 8
- 241000160321 Parabacteroides Species 0.000 claims abstract description 8
- 241000692844 Prevotellaceae Species 0.000 claims abstract description 8
- 241000192031 Ruminococcus Species 0.000 claims abstract description 8
- 210000003205 muscle Anatomy 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims description 33
- 210000004556 brain Anatomy 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 230000003143 atherosclerotic effect Effects 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 241001013934 Erigeron breviscapus Species 0.000 claims description 8
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 claims description 8
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 8
- 244000131316 Panax pseudoginseng Species 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 241001202853 Blautia Species 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 241000681946 Rhododendron dauricum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 241000218628 Ginkgo Species 0.000 abstract description 8
- 235000003143 Panax notoginseng Nutrition 0.000 abstract description 2
- 241000180649 Panax notoginseng Species 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 28
- 238000010186 staining Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000208422 Rhododendron Species 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 241000723353 Chrysanthemum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000132521 Erigeron Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000364 effect on atherosclerosis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002644 neurohormonal effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and discloses a novel application of a lamp silver brain-invigorating composition. The Lamp Yinnaotong composition comprises herba Erigerontis, folium Ginkgo, notoginseng radix, and radix Rhodiolae. The application of the lamp silver brain-dredging composition in preparing medicines for preventing and/or treating atherosclerosis has the effects of obviously inhibiting atherosclerosis plaques and regulating blood fat, and meanwhile, the lamp silver brain-dredging composition has a protective effect on ileum tissues and/or colon tissues, can obviously increase the average goblet cell number, the villus length and the muscle layer thickness of each villus of the ileum, and can increase the goblet cell number of each crypt of the colon tissues. The application of the lamp silver brain-on composition in preparing medicines for regulating intestinal flora can obviously raise the abundance of Alloprevotella _Bactroides, ruminococcus, prevotellaceae _NK3B31_group and Parabacteroides bacteria at the genus level and obviously reduce the abundance of Blmotia and Desulfovibrio bacteria. The novel application of the Lamp silver brain-dredging composition disclosed by the invention expands the range of clinical application of the lamp silver brain-dredging composition and has a wide application prospect.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a novel application of a lamp silver brain-invigorating composition.
Background
The incidence and mortality of cardiovascular diseases have been the first global and have been on the rise year by year. Atherosclerosis is an important factor causing cardiovascular diseases, and lesion sites mainly involve large and medium-sized arteries, and are mostly caused by fat metabolic disorder and nerve vascular dysfunction, and are manifested by intimal thickening, foam cells appear, and atherosclerosis plaques are formed. Plaque projects into the lumen of the artery causing vascular stenosis, plaque rupture is secondary to initiation of atherothrombosis, and serious cardiovascular and cerebrovascular clinical events are initiated. Atherosclerosis is the main pathological basis and key link of cardiovascular disease, and the formation and shedding of plaque on the wall of the vessel are the most important factors of serious cardiovascular events. Thus, the prevention and treatment of atherosclerosis is a major task in the world today.
Atherosclerosis is a complex multi-factor disease, the specific pathogenesis of which is not clear at present, but researches show that intestinal flora plays an important role in the occurrence and development of atherosclerosis. The intestinal tract is the largest endocrine neurohormonal network in humans, and the intestinal flora plays a key role in maintaining homeostasis. Intestinal flora promotes many necessary and beneficial physiological processes, such as the digestion of macronutrients and the synthesis of some vitamins, while there is a great deal of evidence that intestinal flora plays a role in the development of undesirable phenotypes. In particular, significant changes in the structure and function of the microflora are associated with a variety of disease states. It has been found that the composition and structure of intestinal microorganisms in coronary atherosclerotic patients vary significantly from those of healthy individuals. The abundance of three clusters of microorganisms in coronary atherosclerotic patients is significantly increased, represented by enterobacteriaceae, oral-derived bacteria (such as streptococcus) and clostridium, which significantly inhibit the enrichment of some beneficial bacteria, such as clostridium tenecum. More importantly, early sequencing studies by researchers showed that bacterial DNA was found in human atherosclerotic plaques, and that these bacteria might be from the gut or oral cavity.
The intestinal microbial barrier is composed of a healthy intestinal flora. In a healthy state, intestinal barrier function is maintained by physical factors including the tight junctions between epithelial cells, the mucus produced, and mucosal immunity. When the intestinal flora is dysregulated, the expression of the tight junction protein is inhibited, so that the permeability of the intestinal tract is increased. According to the concept of intestinal leakage, impaired intestinal barrier function leads to bacterial products entering the host circulation, leading to a pro-inflammatory state. Studies have shown that the intestinal barrier function of ApoE -/- mice in the atherosclerosis model is impaired, thereby exacerbating the progression of atherosclerosis. Under stimulation of a high-fat diet, the intestinal microbiota produces endotoxins, inducing vascular inflammation and metabolic disorders via CD 14. Endotoxins also participate in toll-like receptor-4 and activate signaling pathways, leading to the expression of inflammatory cytokines.
A Chinese medicine in the form of capsule for treating apoplexy, such as the "YinNaotong" capsule, is prepared from 4 Chinese-medicinal materials including fleabane herb, gingko leaf, notoginseng, etc.
At present, the medicinal composition of the baobantong is mostly applied to the treatment of cerebral apoplexy, and has a certain clinical application basis, but no literature reports whether the medicinal composition of the baobantong has an intervention effect on atherosclerosis or not, and no literature reports whether the medicinal composition of the baobantong can regulate intestinal flora or can protect ileum tissues and/or colon tissues or not.
The present invention has been made in view of this.
Disclosure of Invention
The invention aims to solve the technical problem of overcoming the defects of the prior art and providing a new application of a lamp silver brain-dredging composition. The invention discovers that the dencichine brain-dredging composition has the effect of inhibiting atherosclerosis and also has the effects of regulating intestinal flora and protecting ileum tissues and/or colon tissues.
In order to solve the technical problems, the invention adopts the basic conception of the technical scheme that:
The first object of the invention is to provide an application of a lamp silver brain-invigorating composition in preparing medicines for preventing and/or treating atherosclerosis.
The Lamp YinNaotong composition consists of 4 traditional Chinese medicinal materials of erigeron breviscapus, ginkgo leaf, pseudo-ginseng and dahurian rhododendron leaf, and the existing lamp YinNaotong capsule developed on the basis is loaded in the national pharmaceutical standard WS-10843 (ZD-0843) -2002-2012Z. At present, the traditional Chinese medicine is mainly used for treating cerebral apoplexy. Atherosclerosis is the symptom of the deficiency and the excess, viscera qi deficiency is the principal, phlegm, blood stasis and toxin are the principal, and phlegm, blood stasis and toxin are often caused by each other, so the atherosclerosis is often a comprehensive treatment clinically, and is used comprehensively for resolving phlegm, reducing blood fat, promoting blood circulation by removing blood stasis, clearing heat, detoxicating, tonifying qi and nourishing yin.
Experiments show that the lamp silver brain-dredging composition has an interference inhibiting effect on atherosclerosis, and can be used for preparing medicines for preventing and/or treating atherosclerosis.
Further scheme, the application of the lamp silver brain-invigorating composition in preparing medicines for inhibiting atherosclerosis plaques.
Further scheme, the application of the lamp silver brain-invigorating composition in preparing medicines for regulating atherosclerosis blood lipid level.
A second object of the present invention is to provide the use of a lamp silver brain-on composition for the preparation of a medicament for protecting ileal tissue and/or colonic tissue.
Further aspects, the ileum tissue is an atherosclerotic ileum tissue, and protecting the atherosclerotic ileum tissue comprises increasing the average goblet cell number per villus of the ileum, increasing villus length, and increasing muscle layer thickness.
In a further aspect, the colon tissue is atherosclerotic colon tissue, and protecting the atherosclerotic colon tissue comprises increasing the number of crypt goblet cells per colon tissue.
Further scheme, the application of the dendranthema pallidum composition in preparing medicines for regulating intestinal flora of atherosclerosis;
Preferably, the lamp silver brain-invigorating composition improves the abundance of intestinal probiotics and reduces the abundance of harmful flora;
Preferably, the lamp silver brain-on composition increases Alloprevotella, bacterioides, ruminococcus, prevotellaceae _nk3b31_group and Parabacteroides bacteria abundance, and decreases Blautia and Desulfovibrio bacteria abundance.
The second object of the invention is to provide an application of the lamp silver brain-invigorating composition in preparing medicines for regulating intestinal flora.
Further scheme, the application of the lamp silver brain-activating composition in preparing medicines for regulating intestinal flora to intervene in atherosclerosis.
Further aspects, the light silver brain-on composition increases Alloprevotella, bacilli, ruminococcus, prevotellaceae _nk3b31_group and Parabacteroides bacteria abundance, and the light silver brain-on composition decreases Blautia and Desulfovibrio bacteria abundance.
Further scheme, the Lamp silver brain composition consists of erigeron breviscapus, ginkgo leaf, pseudo-ginseng and dahurian rhododendron leaf;
Further, the lamp silver brain-invigorating composition comprises: 300-600 parts of erigeron breviscapus, 300-600 parts of dahurian rhododendron leaf, 300-600 parts of ginkgo leaf and 100-300 parts of pseudo-ginseng;
preferably, the lamp silver brain-invigorating composition comprises: 400-550 parts of erigeron breviscapus, 400-550 parts of dahurian rhododendron leaf, 400-550 parts of ginkgo leaf and 150-250 parts of pseudo-ginseng;
More preferably, the lamp silver brain-on composition comprises: 500 parts of erigeron breviscapus, 500 parts of dahurian rhododendron leaf, 500 parts of ginkgo leaf and 200 parts of pseudo-ginseng.
Preferably, the lamp silver brain-invigorating composition further comprises pharmaceutically acceptable auxiliary materials;
preferably, the dosage form of the dencichine brain-invigorating composition is selected from capsules, tablets, injections, powders, pills, granules or oral liquids.
Preferably, the dencichine composition is dencichine capsule, more preferably, the approval document of the dencichine capsule is: chinese medicine standard Z20026228. After the technical scheme is adopted, compared with the prior art, the invention has the following beneficial effects:
1. The invention discovers that the lamp silver brain-activating composition has an interference inhibiting effect on atherosclerosis, and specifically:
(1) The lamp silver brain-invigorating composition has the effect of obviously inhibiting the atherosclerosis plaque;
(2) The Lamp silver brain-invigorating composition has the function of regulating the blood lipid level of an atherosclerosis mouse;
2. The lamp silver brain-invigorating composition has protective effect on ileum tissue and colon tissue.
The lamp silver brain composition has obvious protection effect on the ileum tissue of an atherosclerosis mouse, and can obviously increase the average goblet cell number, the villus length and the myolayer thickness of each villus of the ileum.
The lamp silver brain composition has a certain protection effect on colon tissues of atherosclerosis mice, and can increase the number of cup cells of each crypt of the colon tissues.
3. The dencichine brain-on composition has an effect of regulating intestinal flora, specifically, through 16s rDNA sequencing analysis, the dencichine brain-on capsule is found to obviously increase the abundance of beneficial flora, and at the genus level, the abundance of Alloprevotella _Bactroides, ruminococcus, prevotellaceae _NK3B31_group and Parabacteroides flora can be obviously increased, and the harmful flora is obviously reduced: blautha and Desulfovibrio are abundant. The lamp silver brain-invigorating composition has regulating effect on atherosclerosis related intestinal flora.
The novel application of the Lamp silver brain-dredging composition disclosed by the invention expands the range of clinical application of the lamp silver brain-dredging composition (such as a lamp silver brain-dredging capsule) and has a wide application prospect.
The following describes the embodiments of the present invention in further detail with reference to the accompanying drawings.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention. It is evident that the drawings in the following description are only examples, from which other drawings can be obtained by a person skilled in the art without the inventive effort. In the drawings:
In fig. 1a is a mouse aortic substantially oil red O staining; b is the mouse aortic gross plaque area statistics; c is rat aortic root HE staining; d is the red O staining of the aortic root oil of the mice; e is the aortic root Masson' strichrome staining of the mice; f is the statistics of the aortic root plaque and necrotic core duty ratio of the mice; G. rat aortic root lipid deposition, plaque fibrosis ratio statistics (note: P < 0.01;: < 0.05);
FIG. 2 is serum blood lipid levels of mice in each group (note: P < 0.01; P < 0.05);
Fig. 3 a is ileal tissue H & E staining; b is an ileal tissue alisxin blue stain; c is the average goblet cell number of each ileal villus, the average length of the ileal villus, and the average muscular layer thickness (note: P < 0.05; P < 0.01; P < 0.0001; nsP > 0.05);
FIG. 4A shows H & E staining of colon tissue; b is an alisxin blue stain of colon tissue; c is the average goblet cell number per crypt, the average crypt depth of the colon, the average myolayer thickness of the colon (note: nsP > 0.05);
in fig. 5a is the Chao1 index; b is PCoA principal component analysis; c is the relative abundance at the gate level for each group; d is the relative abundance at the genus level for each group; e is a species with significant differences at the genus level (note: P < 0.05; P < 0.01).
It should be noted that these drawings and the written description are not intended to limit the scope of the inventive concept in any way, but to illustrate the inventive concept to those skilled in the art by referring to the specific embodiments.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions in the embodiments will be clearly and completely described with reference to the accompanying drawings in the embodiments of the present invention, and the following embodiments are used to illustrate the present invention, but are not intended to limit the scope of the present invention.
The Lamp silver brain-invigorating composition comprises any Chinese herbal compound preparation consisting of 4 Chinese herbal medicines of erigeron breviscapus, ginkgo leaf, pseudo-ginseng and dahurian rhododendron leaf, is not limited to the dosage form, can be a capsule, can be a tablet or other dosage forms. The invention specifically adopts the lamp silver brain-invigorating capsule for test.
1. Lamp silver brain-invigorating composition (lamp silver brain-invigorating capsule)
Prescription: 500g of erigeron breviscapus, 500g of dahurian rhododendron leaf, 500g of ginkgo leaf and 200g of pseudo-ginseng.
The preparation method comprises the following steps: soaking the four materials in water for 4 hours, decocting for three times, each time for 2 hours, combining the decoctions, filtering, adding ethanol into the filtrate to ensure that the ethanol content reaches 70%, mixing uniformly, standing for 24 hours, filtering, recovering ethanol from the filtrate until no ethanol smell exists, drying under reduced pressure, grinding into powder, adding 100g of starch, 30g of microcrystalline cellulose, 80 g of polysorbate, 0.5g of hydroxypropyl methylcellulose, 2g of magnesium stearate and 17.5g of sodium carboxymethylcellulose, granulating, encapsulating, and making into 1000 granules.
The Lamp silver brain-invigorating capsule used in the following experiments of the present invention is produced by Kunyao group Co., ltd.
2. Experimental method
1. Experimental animal
27 SPF-class ApoE-/-mice, 8C 57 mice, male and female halves were selected at 8 weeks of age, and all mice were from Shanghai Laek animal Co. Raising in the animal experiment center of the hospital in combination with the Yueyang traditional Chinese and Western medicine affiliated to Shanghai traditional Chinese medicine university. Raising temperature: 25+/-2 ℃; humidity: 40% -55%; illumination period: 12h illumination/12 h night alternation. All procedures were in accordance with the institutional animal care committee of the university of chinese medicine, shanghai, ethical (18867).
After 1 week of adaptive feeding with free water intake, 27 ApoE-/-mice were divided into 3 groups by random number: high fat diet group (0.5% CMCNA, HFD), lamp silver brain flux low dose administration group (0.2 g/kg/d, dissolved in 0.5% CMCNA (0.5% sodium carboxymethyl cellulose aqueous solution by mass fraction), designated DYNT-L) and Lamp silver brain flux high dose administration group (1 g/kg/d, dissolved in 0.5% CMCNA, designated DYNT-H), C57 mice were used as normal control group. The administration group was filled with 200ul of the lamp silver brain-invigorating capsules at different concentrations, and the normal control group and the high-fat diet group were administered with 0.5% cmcna in equal volumes for 8 consecutive weeks.
2. Animal treatment
After the last medicine is dried, the feces of each group of mice are collected by rubbing the abdomen and stored in a refrigerator at the temperature of minus 80 ℃. All animals were sacrificed the next day after orbital sampling, mice were fixed with exposed hearts, perfused with 0.9% saline at the apex until clear fluid was shed, and the hearts were peeled off along with the thoracic aorta. The distal ileum and proximal colon of each group of mice were split longitudinally, in half. Randomly selecting one half of mice in each group to leave aorta and colon, and placing the mice in a refrigerator at-80 ℃ for freezing and storing, and carrying out subsequent expression analysis; the aorta and the return colon of the remaining half mice of each group were fixed with 4% paraformaldehyde, paraffin embedded, and subjected to histopathological analysis.
3. Histomorphology analysis
Paraffin tissue of all samples was prepared into 4 μm sections
A.H & E staining for observing pathological changes of aortic and intestinal tissues
Masson's trichrome staining observed the collagen deposition to reflect aortic fibrosis
C. Oil red O staining for observing lipid deposition of aortic plaque
D. aglisine blue staining for observing change of number of goblet cells of intestinal tissue
4. Serum biochemical analysis
After the serum is extracted from the blood of the mice by centrifugation at 3000rpm for 10min, biochemical indexes TC, TG, LDL-C, HDL-C in the serum are detected by using a biochemical kit of a institute of biological engineering built by Nanjing.
5. Fecal 16S rDNA sequencing
Fresh fecal DNA was extracted using QIAAMP FAST DNA Stool Mini Kit and after PCR amplification, 16S rDNA was sequenced using the Miseq System (Illumina, USA). Is completed by Shanghai European biomedical science and technology Co.
3. Experimental results
1. Lamp silver brain dredging capsule with obvious atherosclerosis plaque inhibiting effect
As shown in fig. 1A, the results suggest that the high dose group of the lamp silver brain capsule can significantly inhibit plaque formation in aortic arch and thoracic aorta (P < 0.05) by staining the aorta with substantially oil red O. By H & E staining the aortic root of mice (fig. 1C), it was suggested that significant plaque appeared in all three groups of the aortic roots of mice. Compared with the HFD group, the high-dose group of the lamp silver brain-dredging capsule can obviously reduce the size of atherosclerosis plaque (P is smaller than 0.05), and meanwhile, the high-dose group of the lamp silver brain-dredging capsule can obviously reduce the size of necrotic cores in plaque. As shown in fig. 1D, by oil red O staining of the aortic root of mice, it was suggested that the plaque lipid deposition occurred to varying degrees in all three groups of mice, and that the high dose group of the lamp silver brain capsule significantly reduced plaque lipid deposition (P < 0.05) compared to the HFD group. As shown in fig. 1E, by Masson's trichrome staining of the aortic root of mice, it was suggested that all three groups of mice showed different degrees of fibrosis in aortic root plaques, and that the low-dose and high-dose groups of the lamp silver brain capsule reduced plaque fibrosis levels to some extent compared to the HFD group.
2. Lamp Yinniaotong capsule for regulating blood lipid level of atherosclerosis mice
As shown in FIG. 2, the contents of LDL-C, HDL-C, TC and TG in each group of mice were measured, and the contents of LDL-C, TC and TG in the HFD group were significantly increased (P < 0.05) and the content of HDL-C was significantly decreased (P < 0.05) compared with the C57 group. Compared with HFD group, the high dose group of the lamp silver brain-invigorating capsule can obviously reduce the content of TC and TG (P is less than 0.05), obviously increase the content of HDL-C (P is less than 0.05), and has no effect on LDL-C.
3. The lamp silver brain capsule has obvious protection effect on the ileum tissue of the atherosclerosis mice
H & E and alisxin blue staining are carried out on ileum tissues, and pathological results show that the partial area of the ileum tissues of the HFD group mice are in villus deficiency, partial tissue edema and inflammatory cell infiltration; while the low-dose and high-dose groups of the lamp silver brain-on capsules had a different degree of alleviation of the ileal pathological lesions compared to the HFD group (FIG. 3A). The results of quantitative statistics on average goblet cell number, villus length and muscle layer thickness per villus of ileum tissue suggest that the average goblet cell number, villus length and muscle layer thickness per villus can be significantly increased in the lamp silver brain-on capsule administration group compared to the HFD group (FIGS. 3B-C), and the effect of the lamp silver brain-on high dose group is more significant (P < 0.05).
4. The Lamp silver brain-activating capsule has a certain protection effect on colon tissues of atherosclerosis mice
H & E staining of colon tissue, as shown in FIG. 4A, visible mucosal damage and myometrial damage were seen in HFD group mice colon tissue; the low-dose group and the high-dose group of the lamp silver cerebral general can relieve pathological damage of colon tissues to a certain extent, and the high-dose group has more obvious effect. The number of cup cells per crypt, the depth of crypt and the thickness of muscle layer were quantified separately for colon tissue. The results suggest that the lamp silver brain flux high dose group can increase the number of cup cells per crypt to some extent compared to the HFD group.
5. Lamp Yinniaotong capsule with intestinal flora regulating effect
Through 16s rDNA sequencing analysis, as shown in FIG. 5A, chao1 is a species richness index, which indicates that the flora abundance of the YinNaotong capsule treatment group is obviously increased compared with that of the HFD group, and the result of the main component analysis in FIG. 5B indicates that the flora of the YinNaotong capsule high-dose group and the flora of the HFD group are greatly different. By comparing the changes in abundance at the gate level and the genus level for each group, the results suggested that there was no significant difference between the groups at the gate level and the genus level (P < 0.05), the light silver brain capsule could significantly increase Alloprevotella, the abundance of bacteria, bacteroides, ruminococcus, prevotellaceae _nk3b31_group and Parabacteroides bacteria, significantly decrease Blautia and Desulfovibrio bacteria (fig. 5C-E).
Summary
The Lamp silver brain capsule has remarkable inhibiting effect on the formation of apoE-/-mouse atherosclerosis plaque, has the effect of regulating blood fat, has remarkable improving effect on pathological injury of ileum, and can remarkably increase the average goblet cell number, the villus length and the myometrium thickness of each villus of the ileum. Through 16s rDNA sequencing analysis, the YinNaotong capsule is suggested to obviously raise the abundance of flora, can obviously raise the abundance of Alloprevotella, bactroides, ruminococcus, prevotellaceae _NK3B31_group and Parabacteroides flora at the genus level, and obviously reduce the abundance of Blmotia and Desulfovibrio flora.
The foregoing description is only illustrative of the preferred embodiment of the present invention, and is not to be construed as limiting the invention, but is to be construed as limiting the invention to any simple modification, equivalent variation and variation of the above embodiments according to the technical matter of the present invention without departing from the scope of the invention.
Claims (10)
1. An application of a Lamp silver brain-invigorating composition in preparing medicines for preventing and/or treating atherosclerosis.
2. The use according to claim 1, wherein the lamp silver brain-on composition is used for the preparation of a medicament for inhibiting atherosclerotic plaques.
3. The use according to claim 1 or 2, characterized in that the beveronification composition is used for the preparation of a medicament for regulating the level of atherosclerotic blood lipid.
4. An application of a Lamp silver brain-invigorating composition in preparing medicines for protecting ileum tissue and/or colon tissue.
5. The use according to claim 4, wherein the ileal tissue is an atherosclerotic ileal tissue, comprising increasing the average goblet cell number per villus of the ileum, increasing villus length and increasing muscle layer thickness;
The colon tissue is atherosclerotic colon tissue and the use comprises increasing the number of crypt goblet cells per colon tissue.
6. The use according to any one of claims 1 to 5, wherein the use of a dendranthema morifolium brain-on composition for the preparation of a medicament for modulating the intestinal flora of atherosclerosis;
preferably, the lamp silver brain-on composition improves the abundance of intestinal probiotics and reduces the abundance of harmful bacteria;
Preferably, the lamp silver brain-on composition increases Alloprevotella, bacterioides, ruminococcus, prevotellaceae _nk3b31_group and Parabacteroides bacteria abundance, and decreases Blautia and Desulfovibrio bacteria abundance.
7. An application of a Lamp silver brain-invigorating composition in preparing medicines for regulating intestinal flora.
8. The use according to claim 7, characterized in that the use of a lamp silver brain-on composition for the preparation of a medicament for regulating intestinal flora to intervene in atherosclerosis.
9. The use according to claim 7 or 8, wherein the light silver brain composition increases Alloprevotella, bacterioides, ruminococcus, prevotellaceae _nk3b31_group and Parabacteroides bacteria abundance, decreases Blautia and Desulfovibrio bacteria abundance.
10. The use according to any one of claims 1-9, wherein the dencichine composition consists of erigeron breviscapus, ginkgo leaf, pseudo-ginseng, rhododendron dauricum;
Preferably, the lamp silver brain-invigorating composition further comprises pharmaceutically acceptable auxiliary materials;
Preferably, the dosage form of the lamp silver brain-invigorating composition is selected from capsules, tablets, injections, powders, pills, granules or oral liquids;
More preferably, the lamp silver brain-invigorating composition is a lamp silver brain-invigorating capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211355093.0A CN117982549A (en) | 2022-11-01 | 2022-11-01 | New application of lamp silver brain-dredging composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211355093.0A CN117982549A (en) | 2022-11-01 | 2022-11-01 | New application of lamp silver brain-dredging composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117982549A true CN117982549A (en) | 2024-05-07 |
Family
ID=90889533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211355093.0A Pending CN117982549A (en) | 2022-11-01 | 2022-11-01 | New application of lamp silver brain-dredging composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117982549A (en) |
-
2022
- 2022-11-01 CN CN202211355093.0A patent/CN117982549A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700358B (en) | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN104013681A (en) | Pharmaceutical composition for treating kidney stone | |
| CN101564458B (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN100364594C (en) | Medicine for treating chronic superficial gastritis and peptic ulcer diseases | |
| CN104324125B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| WO2021013270A1 (en) | Pharmaceutical composition for treating polyp | |
| CN111150799A (en) | Composition for preventing and treating hyperuricemia and gout as well as preparation method and application thereof | |
| CN101590218A (en) | A kind of Chinese medicine composition for the treatment of recurrent oral ulceration and preparation method thereof | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN112076249B (en) | Application of perilla leaf extract in preparing medicament for treating inflammatory bowel disease | |
| CN1895433A (en) | Chinese-medicinal composition for treating acne, its preparation and use | |
| CN117982549A (en) | New application of lamp silver brain-dredging composition | |
| CN112755168B (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by helicobacter pylori and preparation method and application thereof | |
| CN100335083C (en) | Pile treating Chinese medicine prepn and its production process | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN101991659A (en) | Preparation with functions of clearing heat and releasing toxin and preparation method | |
| TWI840159B (en) | Composition for treating and/or improving inflammatory intestinal diseases | |
| CN102058676B (en) | Traditional Chinese medicinal extract for treating ulcerative colitis, medicinal composition thereof and preparation method thereof | |
| CN103479824A (en) | Traditional Chinese medicine compound for treating chronic periodontitis and gastritis and preparation method thereof | |
| CN113925952B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating digestive tract tumor | |
| CN114470134B (en) | Compound traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof | |
| CN1279929C (en) | Chinese medicine for treating facial paralysis, preparing method and use | |
| CN113747911B (en) | Pharmaceutical composition for preventing or treating inflammatory bowel disease comprising mixed extracts of Coptidis rhizoma and Schizonepeta tenuifolia as effective ingredients | |
| CN101670046A (en) | Chinese medicinal composition for gastritis and esophagitis and preparation process thereof | |
| CN102091138A (en) | Gastrointestinal tablet and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |